Publications
Open Markets Institute Executive Director Barry Lynn released the following statement regarding the news that the U.S. Federal Trade Commission (FTC) will investigate partnerships between dominant tech giants and artificial intelligence companies, including Microsoft and OpenAI, Amazon and Anthropic, and Google and Anthropic.
Read MoreThe Open Markets Institute filed an amicus brief in two cases currently before the Supreme Court concerning states’ ability to regulate certain companies in the public interest, or as “common carriers”: Moody v. NetChoice and NetChoice v Paxton.
Read MoreCJL Director Dr. Courtney Radsch discusses new legislation in California that may allow for newsroom advantages over Big Tech.
Read MoreOpen Markets Institute was listed among the groups that have signed onto a letter opposing Koch Industries’ purchase of OCI Global’s Iowa Fertilizer Company for $3.6 billion, which would further consolidate the industry and damage competition and prices
Read MorePolicy Director Phillip Longman highlights the need for price regulation in the airline industry alongside the milestone decision by a federal judge to block JetBlue’s acquisition of Spirit Airlines.
Read MoreIn this issue, we preview what to expect from the antimonopoly movement in 2024, predicting more aggressive actions against mergers and a deflation of the AI hype.
Read MorePolicy Director Phillip Longman publishes a featured piece largely based on a pivotal report published by Longman/Open Markets and the Center for Journalism & Liberty at Open Markets on how the breakdown of journalism's business model is not the result of inherent features of the internet or of digital technology.
Read MoreMarketplace quoted Open Markets’ food systems policy director Claire Kelloway on how the proposed merger between grocery store giants Kroger and Albertsons would increase the company’s negotiating power with brands.
Read MoreLegal director Sandeep Vaheesan discusses about a new book that shows how Uber was a symbol of a neoliberal philosophy that neglected public funding and regulation in favor of rule by private corporations.
Read MoreReporter Austin Ahlman explains the battle between station ownership and the few remaining opportunities to reinstate regulatory practices on broadcasting companies by the FCC.
Read MoreWelcome to our final installment of The Corner for 2023. Over the course of the year, our team continued to drive the reinvigoration of antimonopoly law around the world, as well as policies reining in Big Tech. See some of the ways we did so below.
Read MoreA coalition of civil society groups including Open Markets, the Irish Council for Civil Liberties, Mozilla, Foxglove and more wrote to the UK’s Competition and Markets Authority (CMA) calling for a full investigation into Microsoft's $13 billion monopolistic partnership with OpenAI.
Read MoreLegal director Sandeep Vaheesan and policy counsel Tara Pincock co-published a powerful piece emphasizing that even the biggest publishers are no match for Amazon’s death grip on the book market.
Read MoreOpen Markets Industrial Policy Program Manager Audrey Stienon penned a piece in The American Prospect on the pros and cons of California’s close partnership with Civica Rx, as the state begins to manufacture insulin in an effort to lower costs.
Read MoreFood and agriculture systems program manager Claire Kelloway co-wrote a paper with senior fellow at American Economic Liberties Project, Matthew Buck, examining exclusionary payments as an unfair tactic used by dominant retailers to abuse their market power to corner food retail markets and marginalize new and community-based producers.
Read MoreThe American Prospect cited Open Markets’ comments to US federal agencies on the new merger guidelines in their coverage.
Read MoreOpen Markets Legal Director Sandeep Vaheesan put out a statement on the final 2023 merger guidelines from the US Department of Justice and Federal Trade Commission.
Read MoreThe Open Markets Institute welcomed the announcement that gene sequencing company Illumina will sell cancer test developer Grail following inquiries from antitrust regulators.
Read More
